Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma
Sunday, October 9, 2016 - 05:02
in Health & Medicine
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results.